EVT EXECUTE EVT INNOVATE CAREER INVEST ABOUT DE EN Pharma partnerships EVT INNOVATE PIPELINE OF PRODUCT OPPORTUNITIES PHARMA PARTNERSHIPS ANTI-INFECTIVES DERMATOLOGY DIABETES AND DIABETIC COMPLICATIONS INFLAMMATION AND IMMUNOLOGY NEUROSCIENCE ONCOLOGY R&D PROJECTS IPSC PLATFORM SPIN-OFFS AND OTHER HOLDINGS BRIDGES DDUP Evotec is committed to delivering solutions for some of the largest and most pressing global medical needs. With EVT Innovate, the Company brings forward the most promising scientific ideas to make a difference in key medical areas. In its research initiatives, Evotec is progressing its pre-clinical assets to potential entry points for drug discovery alliances and partners those to pharmaceutical companies for upfront payments, on-going research fees and significant milestones and royalties. Through this strategy, Evotec is building a pipeline without bearing the extensive financial risk normally involved in such projects. ANTI-INFECTIVES BAYER - HAPLOGEN/ TARGETPICV In November 2012, Evotec and Haplogen GmbH signed a collaboration agreement to discover and develop small molecules against viral infectious diseases. Under the agreement, Haplogen and Evotec co-develop drugs against a human protein that is essential for pathogenic viruses to infect their host cell. This protein was discovered by Haplogen's powerful proprietary technology to identify host factors for infectious human pathogens. Evotec further develop Haplogen's lead compounds and apply its drug discovery platform to find additional small molecule inhibitors. Terms of the partnership were not disclosed. In August 2018, Haplogen entered into a multi-year drug discovery and development collaboration with Bayer AG to identify new therapeutics with applications in pulmonary diseases such as chronic obstructive pulmonary disease (“COPD”). Evotec and Haplogen’s target-based approach will be broadened under the terms of the new Haplogen collaboration with Bayer. As part of the new Haplogen collaboration, Bayer receives an exclusive license to worldwide rights to programmes developed within the collaboration between Haplogen and Evotec. Evotec will participate in undisclosed upfront as well as potential milestone and royalty-based payments from Haplogen. DERMATOLOGY ALMIRALL In September 2018, Evotec and Almirall announced that they have entered into a research collaboration to discover and develop first-in-class therapeutics through a novel approach to disrupt cell signalling, that is expected to deliver highly potent and durable treatments for debilitating dermatology diseases such as psoriasis and atopic dermatitis. The collaboration combines Evotec’s cutting-edge drug discovery and pre-clinical development platforms with Almirall’s leading expertise in dermatology diseases. Under the terms of the agreement, Evotec will receive research funding and may be eligible to receive discovery, pre-clinical, clinical and sales milestone payments as well as tiered royalties. DIABETES AND DIABETIC COMPLICATIONS SANOFI/ TARGETBCD In August 2015, Evotec and Sanofi entered into a strategic collaboration in the field of diabetes. The goal of this collaboration is to develop a beta cell replacement therapy based on functional human beta cells derived from human stem cells. In addition, Sanofi and Evotec will also use human beta cells for high-throughput drug screening to identify beta cell active small molecules or biologics. Both companies will make significant contributions to this collaboration in terms of expertise, platforms and resources. The collaboration further enhances and complements Sanofi's extensive diabetes portfolio and extends Evotec's metabolic disease and stem cell-based drug discovery programmes. The agreement between Evotec and Sanofi triggers an upfront payment of EUR 3 m, potential pre-clinical, clinical, regulatory and commercial milestones which could total over EUR 300 m as well as significant royalties and research payments. In April 2017, Evotec has reached an important milestone, triggering a payment of EUR 3.0 m to Evotec, for achieving pre-clinical proof-of-concept. In June 2018, Evotec has reached its second beta cell therapy milestone, resulting in a payment of € 3 million to Evotec. This milestone was triggered after Evotec met pre-agreed critical success criteria for a potential manufacturing process for generation of human induced pluripotent stem cell (iPSC)-derived beta cells, including the demonstration of upscaling potential and suitability of the cell product for encapsulated beta cell function in diabetes models. BAYER/ CURENEPHRON In September 2016, Evotec announced that Evotec and Bayer have entered into a five-year, multi-target research partnership. The goal is the development of multiple clinical candidates for the treatment of kidney diseases such as chronic kidney disease in diabetes patients. Both companies will contribute novel drug targets and a comprehensive set of high-quality technology platforms to jointly develop innovative treatment options for these severe conditions. The partners will share responsibilities during pre-clinical development of potential clinical candidates. Under the terms of the agreement, Bayer received exclusive access to selected candidates as well as to Evotec’s CureNephron target pipeline. Bayer will be responsible for any subsequent clinical development and commercialisation. Evotec will receive a minimum of € 14 m over the contract period including research payments and an undisclosed licence fee. In addition, Evotec is eligible to receive pre-clinical, clinical and sales milestones of potentially over € 300 m as well as tiered royalties of up to low double-digit percentage of net sales. ASTRAZENECA/ KIDNEY DISEASE In October 2013, Evotec entered into an agreement with AstraZeneca in the field of kidney diseases. Initial focus of the alliance will be exploring compounds and targets with novel mechanisms that have disease-modifying potential for the treatment of chronic kidney disease. Under the terms of this licence and collaboration agreement, AstraZeneca received access to a selected series of molecules identified in a screening effort, which is part of Evotec's systematic kidney disease initiative. This particular programme has been designed to explore a key mechanism in the field of chronic kidney disease. AstraZeneca provides industrial scope and scale as well as pharmaceutical development expertise and marketing capabilities. The agreement between Evotec and AstraZeneca triggered an undisclosed upfront payment as well as pre-clinical, clinical and regulatory milestones. Evotec is also eligible for additional milestone and royalty payments related to commercialisation. Evotec receives research funding for work that will be conducted in collaboration with AstraZeneca. Specific financial details were not disclosed. INFLAMMATION AND IMMUNOLOGY PFIZER/ FIBROSIS In September 2015 Evotec announced that it has signed an agreement on a four-year research collaboration with Pfizer Inc. in the field of tissue fibrosis. Under the terms of this licence and collaboration agreement, scientists at Evotec and Pfizer explore potential novel mechanisms as targeted anti-fibrotics in multi-organ fibrosis. Evotec contribute its drug discovery platform whereas Pfizer provide key technologies and industrial scope as well as pharmaceutical development and marketing expertise. Financial terms of the collaboration include an upfront payment and potential milestone payments from Pfizer based on the achievement of specific development and sales milestones. SECOND GENOME/ TARGETMB In March 2015, Evotec and Second Genome, Inc. announced a collaboration in small molecule-based discovery and development activities for the treatment of microbiome-mediated diseases. The collaboration comprises the identification and optimisation of novel compounds as well as licence agreements for already existing assets developed by Evotec. Second Genome's unique approach to identify and modulate microbiome-mediated pathways will be further enhanced by the use and the results of Evotec's integrated drug discovery platform. As part of the collaboration, Second Genome and Evotec work together to screen microbiome-mediated targets of interest identified by the Second Genome microbiome discovery platform with Evotec's technology platform, chemical libraries and other pre-clinical capabilities. The agreement between Evotec and Second Genome triggered an undisclosed upfront payment. Evotec is also eligible for pre-clinical, clinical and regulatory milestones as well as royalty payments related to commercialisation. CONBA PHARMACEUTICAL/ EVT401 In May 2012, Evotec AG and CONBA Pharmaceutical Co., Ltd. announced the grant of a development and marketing licence on EVT401, a selective, small molecule P2X7 antagonist, for human indications with exception of ophthalmological, chronic obstructive pulmonary disease (“COPD”) and endometriosis in China. Evotec received a small upfront payment and is eligible for development and commercial milestone payments in excess of € 60 m and tiered double-digit royalties on net sales. The agreement grants CONBA exclusive rights to develop and commercialise the compound for the Chinese market. Evotec will have the right to reference clinical data produced by CONBA Pharmaceutical to support potential further development of EVT401 in other territories. P2X7 receptor antagonism may provide a novel approach for the treatment of inflammatory conditions. Evotec has completed the first Phase I, single dose study of EVT 401 in 2010. CONBA will initiate further clinical trials with EVT401 in China in inflammatory diseases. In July 2013, CONBA received green light from the Chinese government to continue their studies on the EVT401 programme. NEUROSCIENCE CELGENE/ NEURODEGENERATIVE DISEASES In December 2016, Evotec announced that Evotec and Celgene Corporation have entered into a strategic drug discovery and development collaboration to identify disease-modifying therapeutics for a broad range of neurodegenerative diseases. Initial disease areas of focus will include Amyotrophic lateral sclerosis, Alzheimer's disease, Parkinson's disease, and multiple other neurodegenerative disorders. Evotec has built an industrialised iPSC infrastructure that represents one of the largest and most sophisticated iPSC platforms in the industry. Evotec's iPSC platform has been developed over the last five years with the goal to industrialise iPSC-based drug screening in terms of throughput, reproducibility and robustness to reach the highest industrial standards. This effort was enabled by a research collaboration and licence agreement with Harvard University involving world-leading scientists at the Harvard Stem Cell Institute. In particular, a collaboration termed CureMotorNeuron that was initiated in 2013 with the laboratories of Professors Kevin Eggan, PhD, and Lee Rubin, PhD, resulted in significant contributions to the platform. Additional aspects of the platform were built up through Evotec's more than 10-year collaboration with the CHDI Foundation in the field of Huntington's disease. Under the terms of the agreement, Evotec received an upfront payment of $ 45 m. Celgene holds exclusive options to in-license worldwide rights to Evotec programmes developed from the company's compound library. Evotec may be eligible to receive up to $ 250 m in milestones as well as up to low double-digit royalties on in-licensed programmes. As part of the collaboration, Celgene may also elect to screen compounds from its proprietary CELMoD(R) library using Evotec's iPSC platform to evaluate activity in models of neurodegenerative diseases. The initial term of the collaboration is five years. In October 2017, Evotec announced that this strategic alliance has reached a first milestone triggering revenues of $ 5.0 m to Evotec. The milestone is due to the successful completion of a screening campaign using Evotec's induced pluripotent stem cell ("iPSC")-based screening platform. In May 2018, Evotec announced that Celgene decided to extend the collaboration to include additional cell lines, which resulted in a $ 6 m payment to Evotec. In October 2018, Evotec announced that Celgene's decision to extend the collaboration with further cell lines resulted in another $ 6 m payment. DOWNLOADS DDin Evotec-Celgene alliance PDF, 873.0 KB JINGXIN/ EVT201 In October 2010, Evotec AG and Zhejiang JingXin Pharmaceutical Co., Ltd (“JingXin”) entered into a licence and collaboration agreement for EVT201 (a GABAA Receptor Partial Positive Allosteric Modulator), a novel potential treatment for insomnia. The agreement granted JingXin exclusive rights to develop and market the drug candidate in China. In return, Evotec received a small upfront payment, together with commercial milestones and significant royalties. In April 2013, JingXin received approval from the Chinese Center of Drug Evaluation to commence clinical trials with EVT201 and is currently running Phase II clinical trials according to plan. Evotec had previously concluded two Phase II studies, providing positive safety and efficacy results. All development costs are borne by JingXin and Evotec will have the right to reference clinical data produced by JingXin to support potential further development of EVT201 in other territories. ONCOLOGY CELGENE/ SOLID TUMOURS In May 2018, Evotec AG announced that Evotec and Celgene Corporation (“Celgene”) have entered into a long-term strategic drug discovery and development partnership to identify new therapeutics in oncology. Evotec has built one of the industry’s broadest and most innovative pre-clinical discovery and development platforms. This includes in particular an industry-leading phenotypic screening platform with unique compound libraries and associated target deconvolution capabilities. The collaboration intends to leverage these capabilities with an initial focus on solid tumours. Celgene receives exclusive opt-in rights to license worldwide rights to all programmes developed within this collaboration. Under the terms of the agreement, Evotec will receive an upfront payment of $ 65 m and may be eligible to receive significant milestone payments as well as tiered royalties on each licensed programme. APEIRON-SANOFI/ TARGETIMMUNIT In January 2013, Evotec and Apeiron Biologics entered into a research collaboration with the objective of developing immunomodulatory lead compounds for the treatment of cancer. Apeiron Biologics contributed in vitro and in vivo pharmacology expertise to this collaboration while Evotec was responsible for medicinal chemistry as well as chemical proteomics. The collaboration was based on the successful outcome of a phenotypic high-throughput screen previously commissioned by Apeiron Biologics to Evotec. In August 2015, Evotec and Apeiron announced a strategic collaboration with Sanofi to develop novel small molecule-based cancer immunotherapies. This collaboration includes major research and development efforts to advance a first-in-class small molecule approach to treat solid and haematopoietic cancers by enhancing the anti-tumour activity of human lymphocytes. Based on Evotec's technological expertise and Apeiron Biologics' immunological know-how, the collaboration also focuses on the identification of novel small molecule hits and their targets for next-generation therapies in immuno-oncology which are expected to complement the current offerings of checkpoint inhibitors. The agreement triggered two years of substantial research payments for Evotec and Apeiron Biologics with the opportunity to receive pre-clinical, clinical, regulatory and commercial milestones which could total over EUR 200 m as well as royalties upon commercialisation. Thursday, January 3rd 2019 Previous Next 2 °C Alderley Park (Cyprotex) Imprint Privacy Policy Legal notice T&Cs RSS RSS Twitter LinkedIn EVOTEC @EvotecAG To all our Friends, Partners and Colleagues from all of us at @EvotecAG & @cyprotexplc and @aptuit… https://t.co/OAzp9HyHtq 10:10 AM - 20 DECEMBER 2018